Scancell Share Discussion Threads

[the real lozan] 20/9/2023 10:07

"There will be no pullback." -
What a SILLY thing to proclaim.
A sign of desperation if ever WE ALL saw one.
Has someone been reading a history of Stalingrad and thinks 'There will be no pullback.' was a good idea ???
.
REALITY = A 'pullback' is inevitable at some stage ...Everyone with a brain KNOWS it
However, 'everyone / Anyone' with a brain are not those the trHYPE merchant's posts are aimed at.

[markingtime] 20/9/2023 09:57

Since only 6 shares have traded on the notional 15.75p bid, I don't know why they don't go 16 bid.....they are fooling no-one (apart from the ageing wood-chopper, obvs)

[inanaco] 20/9/2023 09:57

Bermuda seems to be getting excited again ..........

but is he a buyer

or is he trusting the wisdom of loz which is now being looked at as a movie after the success of "no stock and two broken barrels" generating a Hedge fund in logs

who is playing the Tin man ..... ?

[inanaco] 20/9/2023 09:50

scancells ISCIB2 has so many NY-ESO- 1 epitopes is because they are MHC1 and 11 so generate CD4 t cells as well


proof of existence

[inanaco] 20/9/2023 09:47

MT i feel sorry for the traders .......... empty of shares

Sorry Colin ....

[inanaco] 20/9/2023 09:46

tyrosinaserelated protein 2 (TRP-2)

is the core epitopes of ISCIB1

but scancell ad GP100 to increase CD4 infiltration to assist TPR2 Cd8 t cells

[markingtime] 20/9/2023 09:46

There will be no pullback. Funds are accumulating, as indicated by the rising trade sizes.

[inanaco] 20/9/2023 09:43

the reason why Scib2 is of interest its because it contains 16 NY-ESO- 1 epitopes

thats why within scancell discussions about combining Scib1 and 2 was a possibility

as far as we are aware scancell is still building Iscib2

[inanaco] 20/9/2023 09:41

BNT111 is composed of four melanoma antigens (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE) and is the most advanced of five clinical-stage FixVac product candidates within BioNTech’s broader development pipeline. The FixVac platform is an off-the-shelf mRNA immunotherapy approach that targets a fixed combination of shared non-mutated tumor-associated antigens specific to each cancer type.

[inanaco] 20/9/2023 09:38

BioNtech data exactly the same cancer setting as Scancell

Of the 17 patients treated with the combination of BNT111 with anti-PD-1, six patients developed a partial response. Treatment with BNT111 resulted in the expansion and activation of circulating tumor-antigen-specific T cells with memory-function that exhibited strong cytotoxic activity against tumor cells. Vaccine-induced T cells displayed a Th1 phenotype which is of importance for cell-mediated immune responses such as activation of antigen-specific cytotoxic T cells.

[inanaco] 20/9/2023 09:25

funny all these traders desperate for a pull back ......... and getting nowhere

i wonder when they will shift to buying again ....... opps your shares are gone mate !

[marcusl2] 20/9/2023 09:23

This stunning data is on unresectable metastatic melanoma so we should blow away the competition in that and resectable plus move to earlier lines of treatment.

The earlier trial of Scib.. In a Phase 1/2 clinical trial, 14 out of 16 resected patients (89%) survived for more than 5 years following vaccination with SCIB1



Moderna and BioNTech are not targeting
the same market. They are in resectable
melanoma or first or second line in
combination with anti-PD1

Moderna/Merck are testing the vaccine in melanoma patients whose tumors were surgically removed before being treated with either the drug-vaccine combination or Keytruda alone.

The vaccine is tailored for each patient to generate T-cells, a key part of the body's immune response, based on the specific mutational signature of a tumor. (44%)

BioNTech is also working on the development of a potentially promising mRNA melanoma vaccine, known as BNT111, which is currently being investigated in a phase 2 trial in patients with anti-PD1-refractory/relapsed unresectable Stage 3 or 4 melanoma. This vaccine is also being tested in combination with another drug; this time, the monoclonal antibody medication cemiplimab.

[inanaco] 20/9/2023 09:07

Tf ... In the USA everything is a success till proven otherwise

i prefer to prove the success before we have it ..........

i refer back to my which one has failed posts

SCIB1 or Keytruda


synergy was automatic other experts "did not think so" and sold

[inanaco] 20/9/2023 09:04

i would say the one that is sweating now is BioNtech

[markingtime] 20/9/2023 08:56

One other aspect of BMS etc....BMS may have a particular interest in SCIB1, but a whole company deal might enable them to develop new revenue streams that might otherwise accrue to other major pharmas. So taking everything may strengthen a company's competitive position versus other major pharmas.To me, that indicates a very large bid premium, especially from a baseline share price that is even more "derisory" than it was six months ago.

[torquayfan] 20/9/2023 08:54

Inan thanks for that update on Inovio - maybe they'll be consigned to history in due course !

[phoenixs] 20/9/2023 08:44

I do not envisage Scancell being an independent entity for much longer. Maybe next year?

[rogerbridge] 20/9/2023 08:43

I am still concerned over long term safety of the mRNA covid vaccines. My daughter has not been the same since her last shot.
Thant’s not for discussion here though.
I would like to see a Scancell Covid vaccine, but it will have to wait for resources.

[inanaco] 20/9/2023 08:40

Take inovio ........ its DNA vaccine has consumed some £700m in development costs and trials ... each failure promoting further additions to try and make it work IL-12 for instance

but the end result ... Inovio Mcap is now smaller than scancell

all Hype i am afraid driven like punny7 does .. Marketing snake oil

BioNtech are doing the same adding more complexity to try and get it to work

they are not there yet

[rogerbridge] 20/9/2023 08:36

That’s positive then.

[inanaco] 20/9/2023 08:36

and so far MRNA has not produced significant efficacy in cancer

[inanaco] 20/9/2023 08:32

mRNA personalised vaccines have their uses and are in favour with regulators and government.

?

no different to us mate ......

Biontech did a deal with the government .... but its not a cash give away deal just easier access to trials with the NHS

but look how adaptable MHRA is being Iscib1 pretty much been nodded through hopefully